Background: Gastric adenocarcinoma remains a global health burden with high mortality, while effective targeted therapies are still limited. Claudin-18.2 is a transmembrane tight-junction protein selectively expressed in normal gastric mucosa and retained in gastric adenocarcinoma. Its role as a novel therapeutic target, including zolbetuximab, highlights the importance of investigating claudin…